The Opioid Antagonist Naltrexone Improves Murine Inflammatory Bowel Disease
Open Access
- 1 January 2008
- journal article
- research article
- Published by Taylor & Francis in Journal of Immunotoxicology
- Vol. 5 (2) , 179-187
Abstract
Inflammatory bowel disease (IBD) is a condition of the intestine with significant morbidity. Although hereditary, environmental, immunologic, and bacterial factors have been implicated, the etiology of IBD remains unknown. Since opioid peptides modulate inflammatory cytokine production and opioid antagonists promote tissue growth and repair, we hypothesized the opioid antagonist naltrexone could reduce inflammation of the bowel. Using a chemically-induced mouse model of IBD, C57BL/6J mice received either untreated drinking water or water containing 2% dextran sulfate sodium (DSS) in two parallel regimens modeling moderate and severe colitis. After colitis was established, animals in the moderate colitis study were administered either saline (control) or naltrexone (NTX; 8 or 400 μ g/kg) daily, while those in the severe colitis study received 0.1 or 10 mg/kg NTX. DSS-treated animals had significant weight loss (p = 0.006) and higher disease activity index (DAI) scores (p < 0.001) compared to water controls. However, NTX treatment of mice with moderate colitis resulted in less weight loss, lower DAI scores, and less histologic evidence of inflammation compared to controls. Significantly, elevated levels of colonic RNA for pro-inflammatory cytokines interleukin (IL)-6 and IL-12 were also decreased toward normal with NTX. Similar to patients with severe and unresponsive disease, animals in the severe colitis study did not significantly respond to treatment. Thus, NTX therapy reverses physical symptoms, histologic evidence, and molecular markers of inflammation in moderate colitis. The mechanism by which NTX acts to reverse colitis is related in part to the decreased expression of pro-inflammatory cytokines.Keywords
This publication has 39 references indexed in Scilit:
- Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?Gut, 2007
- Inflammatory bowel disease: past, present, and futureJournal of Gastroenterology, 2007
- Review article: biological drugs in Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2006
- Nuclear Factor κB Signaling in Opioid Functions and Receptor Gene ExpressionJournal of Neuroimmune Pharmacology, 2006
- The opioid antagonist naltrexone blocks acute endotoxic shock by inhibiting tumor necrosis factor-α productionBrain, Behavior, and Immunity, 2004
- The Immunology of Mucosal Models of InflammationAnnual Review of Immunology, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Inhibition of the respiratory burst in mouse macrophages by ultra-low doses of an opioid peptide is consistent with a possible adaptation mechanismFEBS Letters, 1994
- Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporinDigestive Diseases and Sciences, 1993
- Respiratory burst inhibition in human neutrophils by ultra‐low doses of [D‐Ala2]methionine enkephalinamideFEBS Letters, 1991